Gonorrhea is a common bacterial sexually transmitted disease that causes painful urination, discharge, and can lead to serious complications including infertility if left untreated. Whether you’re experiencing symptoms suggesting gonorrhea, need testing after potential exposure, require treatment for a positive diagnosis, or want comprehensive screening including gonorrhea as part of sexual health evaluation, prompt medical care provides accurate diagnosis through testing, effective antibiotic treatment that cures infection, partner notification guidance, and prevention strategies—all delivered by English-speaking doctors in a completely confidential, judgment-free environment. Our specialized sexual health services offer same-day testing with rapid results, immediate treatment when positive, management of antibiotic-resistant strains, and comprehensive STD screening addressing multiple infections simultaneously. With private consultations, hotel visit options for maximum discretion, and expert care for complications, we help international patients overcome gonorrhea quickly while preventing transmission and long-term health consequences.

Understanding Gonorrhea

Gonorrhea is a bacterial infection caused by Neisseria gonorrhoeae that primarily affects the urethra, cervix, rectum, and throat, transmitted through vaginal, anal, and oral sexual contact.

How gonorrhea spreads:

Unprotected vaginal, anal, or oral sex with infected partner.

Contact with infected genital fluids.

Mother-to-baby transmission during childbirth (causing eye infection in newborns).

Cannot spread through toilet seats, sharing drinks, or casual contact.

Why gonorrhea is concerning:

High prevalence worldwide with increasing rates.

Often asymptomatic, especially in women, leading to unknowing transmission.

Increasing antibiotic resistance making treatment more challenging.

Serious complications if untreated: Pelvic inflammatory disease (PID), infertility, ectopic pregnancy, chronic pain in women; epididymitis and infertility in men; disseminated gonococcal infection affecting joints, skin, heart.

Increases HIV transmission risk threefold.

Why travelers contract gonorrhea:

Sexual encounters with new partners during travel.

Inconsistent condom use.

Sex work and sex tourism.

Alcohol and substance use impairing judgment.

False sense of security with partners who appear healthy (many carriers are asymptomatic).

Different prevalence rates and antibiotic resistance patterns than home countries.

Recognizing Gonorrhea Symptoms

Gonorrhea symptoms vary dramatically by gender and infection site, with many infections causing no symptoms at all.

Symptoms in men:

Urethral gonorrhea (most common):

Burning sensation during urination (dysuria)
White, yellow, or green discharge from penis
Painful or swollen testicles (less common)
Symptoms typically appear 2-14 days after exposure

Rectal gonorrhea:

Anal discharge
Anal itching
Soreness
Bleeding
Painful bowel movements
Often asymptomatic

Pharyngeal (throat) gonorrhea:

Sore throat
Usually asymptomatic

Symptoms in women:

Cervical/urogenital gonorrhea:

Increased vaginal discharge (white, yellow, or green)
Burning or pain during urination
Vaginal bleeding between periods
Painful intercourse
Lower abdominal or pelvic pain
50-70% of women have NO symptoms

Rectal gonorrhea:

Same as in men, often asymptomatic

Pharyngeal gonorrhea:

Usually asymptomatic

Asymptomatic infections:

Up to 50% of men have no symptoms initially.

50-70% of women are completely asymptomatic.

Asymptomatic individuals unknowingly transmit infection.

This is why screening after potential exposure is crucial regardless of symptoms.

Complications (untreated gonorrhea):

Pelvic inflammatory disease (PID) in women:

Infection spreading to uterus, fallopian tubes, ovaries
Severe pelvic pain, fever
Infertility (scarring blocks fallopian tubes)
Ectopic pregnancy risk
Chronic pelvic pain

Epididymitis in men:

Testicular inflammation and pain
Potential infertility

Disseminated gonococcal infection (rare):

Bacteria spreading through bloodstream
Joint pain and swelling (septic arthritis)
Skin lesions
Fever
Can affect heart valves (endocarditis)
Medical emergency

Increased HIV susceptibility and transmission.

Diagnosing Gonorrhea

Accurate testing identifies infection and guides appropriate treatment.

Testing methods:

Nucleic acid amplification tests (NAAT) – most sensitive and specific:

Urine sample:

First-catch urine (first part of urination)
Non-invasive option for urethral gonorrhea
Highly accurate
Most common testing method for men

Swab samples:

Urethral swabs (men)
Cervical or vaginal swabs (women)
Rectal swabs (for anal exposure)
Throat swabs (for oral exposure)
Self-collected vaginal swabs are accurate alternative
More sensitive than urine for women

Results typically available within 1-3 days.

Culture (less common):

Growing bacteria from sample
Used when antibiotic resistance suspected
Necessary for testing antibiotic sensitivities
Takes longer (2-7 days)
Required for treatment failure cases

Testing sites based on sexual practices:

Heterosexual men: Urine or urethral swab.

Heterosexual women: Cervical/vaginal swab or urine.

Men who have sex with men: Urine/urethral swab PLUS rectal swab PLUS throat swab.

Anyone engaging in receptive anal sex: Rectal swab.

Anyone engaging in receptive oral sex: Throat swab.

Comprehensive testing covers all potential infection sites based on sexual behaviors.

When to test:

Test 1-2 weeks after potential exposure for accurate results.

NAAT tests can detect infection within one week of exposure.

If symptoms present: Test immediately regardless of timing.

Routine screening recommended for:

Sexually active women under 25 annually
Men who have sex with men every 3-6 months
Anyone with new or multiple partners
Anyone with STD symptoms
Pregnant women

Concurrent testing:

Always test for other STDs simultaneously:

Chlamydia (often coexists with gonorrhea)
HIV
Syphilis
Hepatitis B and C

Testing accuracy:

NAAT tests are 95-99% sensitive and specific.

False negatives rare but possible if tested too early.

Testing multiple sites increases detection.

Gonorrhea Treatment

Antibiotic treatment cures gonorrhea, but increasing resistance requires specific protocols.

Current treatment guidelines:

First-line treatment (due to increasing resistance):

Ceftriaxone 500mg intramuscular injection (single dose)

PLUS

Doxycycline 100mg orally twice daily for 7 days (treats possible chlamydia coinfection and provides additional gonorrhea coverage)

This dual therapy addresses:

Antibiotic-resistant gonorrhea strains
Common chlamydia coinfection (up to 40% have both)
Ensures treatment success

Alternative regimens:

For ceftriaxone allergy:

Gentamicin 240mg IM single dose plus azithromycin 2g oral single dose

For treatment failures:

Higher dose ceftriaxone or alternative antibiotics based on culture sensitivities
Possible IV antibiotics for disseminated infection

Treatment considerations:

Single-dose injections ensure compliance.

Oral-only regimens no longer recommended due to resistance.

Treatment should begin immediately without waiting for culture results.

Partner treatment essential to prevent reinfection.

Treatment response:

Symptoms typically improve within 2-3 days of treatment.

Discharge resolves within one week.

Pain and discomfort decrease rapidly.

No improvement within 3-5 days suggests treatment failure or reinfection—requires reevaluation.

Test of cure:

Recommended for:

Pharyngeal gonorrhea (harder to treat)
Treatment with alternative regimens
Pregnant women
Persistent symptoms

Retest 1-2 weeks after treatment completion.

Ensures infection cleared and doesn’t represent resistant strain.

Antibiotic resistance:

Gonorrhea has developed resistance to nearly every antibiotic class historically used.

Current global concern about ceftriaxone resistance developing.

This is why combination therapy and proper treatment protocols are critical.

Improper treatment (wrong antibiotic, inadequate dose, incomplete course) drives resistance.

Partner Notification and Treatment

Treating sexual partners prevents reinfection and stops transmission chains.

Who needs treatment:

All sexual partners from 60 days before symptom onset or diagnosis.

Even if partner was tested negative—may be in window period before test becomes positive.

Partners should be treated presumptively without waiting for test results (expedited partner therapy).

Expedited partner therapy (EPT):

Providing medication or prescriptions for partners to treat without requiring partner to see doctor.

Reduces reinfection rates significantly.

We can provide partner medications or prescriptions.

Partners should still be encouraged to get tested for other STDs.

Partner notification methods:

Direct notification: You inform partners (most effective).

Anonymous notification: We can provide resources for anonymous partner notification services.

Both methods protect your privacy while ensuring partners get treated.

Preventing reinfection:

Abstain from sexual activity for 7 days after single-dose treatment AND until all partners treated.

Use condoms consistently with any new or potentially infected partners.

Retest 3 months after treatment—reinfection rates are high (20-30%).

Concurrent STD treatment:

Partners should receive treatment for both gonorrhea and chlamydia regardless of test results.

Partners should also be tested for HIV, syphilis, and other STDs.

Preventing Gonorrhea

Understanding prevention protects sexual health and reduces transmission.

Barrier protection:

Condoms are highly effective when used consistently and correctly.

Use for vaginal, anal, and oral sex.

Water-based or silicone lubricants prevent condom breakage.

Internal (female) condoms provide alternative barrier method.

Dental dams for oral-vaginal or oral-anal contact.

Risk reduction strategies:

Mutual monogamy with tested, uninfected partner.

Reducing number of sexual partners.

Avoiding sex with partners who have symptoms.

Pre-exposure communication about STD status and testing.

Regular screening:

Detects asymptomatic infections before transmission or complications.

Recommended annually for sexually active women under 25.

Every 3-6 months for men who have sex with men or anyone with multiple partners.

After any new sexual partner.

PrEP considerations:

PrEP (pre-exposure prophylaxis) prevents HIV, not gonorrhea.

People taking PrEP should continue barrier protection for gonorrhea and other STD prevention.

PrEP users need quarterly STD screening.

Post-exposure considerations:

No proven post-exposure prophylaxis for gonorrhea.

Testing 1-2 weeks after exposure allows early detection and treatment before complications.

Gonorrhea in Special Populations

Certain groups require modified approaches or have specific concerns.

Pregnant women:

All pregnant women should be screened for gonorrhea.

Untreated gonorrhea causes:

Premature rupture of membranes
Preterm delivery
Low birth weight
Neonatal eye infection (ophthalmia neonatorum) causing blindness
Neonatal sepsis

Treatment during pregnancy:

Ceftriaxone injection safe during all trimesters
Doxycycline contraindicated—substitute azithromycin
Test of cure essential
Rescreen third trimester

Newborns of infected mothers receive preventive eye antibiotic ointment at birth.

Men who have sex with men (MSM):

Higher gonorrhea rates, particularly pharyngeal and rectal.

More likely to have antibiotic-resistant strains.

Should be tested at all potential infection sites (urethra, rectum, throat) every 3-6 months.

Higher HIV risk, especially with concurrent gonorrhea.

HIV-positive individuals:

Same treatment as HIV-negative patients.

More frequent screening recommended (every 3-6 months).

Higher risk of treatment failure.

Gonorrhea increases HIV transmission and may increase viral load.

Adolescents:

High gonorrhea rates in 15-24 age group.

Confidential testing and treatment available.

Education about prevention crucial.

Sex workers:

Occupational exposure risk.

Regular screening essential.

Access to barrier protection.

Safe reporting without legal consequences important for public health.

Complications and Long-Term Effects

Understanding potential complications emphasizes treatment importance.

Pelvic inflammatory disease (PID):

Gonorrhea is leading cause of PID in women.

Infection ascends from cervix to uterus, fallopian tubes, ovaries.

Symptoms: Severe pelvic pain, fever, abnormal discharge.

Consequences:

Tubal scarring causing infertility (10-15% after one PID episode, higher with multiple episodes)
Ectopic pregnancy risk (scarred tubes)
Chronic pelvic pain
Tubo-ovarian abscess (may require surgery)

Requires aggressive antibiotic treatment, sometimes hospitalization.

Male infertility:

Epididymitis from gonorrhea can cause:

Testicular damage
Scarring blocking sperm passage
Reduced fertility or sterility

Disseminated gonococcal infection:

Rare but serious systemic infection (bacteremia).

Symptoms:

Fever, chills
Skin lesions (small pustules)
Joint pain and swelling (septic arthritis)
Tenosynovitis (tendon sheath inflammation)

Can progress to endocarditis (heart valve infection) or meningitis.

Requires hospitalization and IV antibiotics.

Higher risk in women, menstruating individuals, immunocompromised.

Reactive arthritis:

Post-infectious arthritis, urethritis, and conjunctivitis following gonorrhea.

Autoimmune reaction to infection.

Can occur despite adequate treatment.

May require rheumatology care.

HIV acquisition and transmission:

Gonorrhea increases HIV acquisition risk 3-5 fold.

Genital inflammation provides entry points for HIV.

In HIV-positive individuals, gonorrhea increases HIV shedding and transmission risk.

Antibiotic Resistance Concerns

Gonorrhea’s resistance to antibiotics is a major global health threat.

Resistance history:

Gonorrhea has sequentially developed resistance to:

Sulfonamides (1940s)
Penicillin (1970s-1980s)
Tetracyclines (1980s)
Fluoroquinolones (2000s)
Azithromycin (2010s)

Ceftriaxone is currently last reliably effective antibiotic.

Current resistance patterns:

Azithromycin resistance now common globally.

Decreased cephalosporin susceptibility emerging.

Multi-drug resistant strains reported.

“Super gonorrhea” strains resistant to all available antibiotics documented.

Why resistance matters:

Untreatable gonorrhea would cause epidemic of PID, infertility, and complications.

Already seeing treatment failures requiring multiple antibiotic attempts.

Need for new antibiotics urgent.

Fighting resistance:

Use proper treatment protocols (dual therapy, adequate doses).

Complete full treatment courses.

Test of cure for treatment failures.

Avoid improper antibiotic use.

Support development of new antibiotics and vaccines.

Gonorrhea vs. Chlamydia

These two STDs often coexist and share similarities but have differences.

Similarities:

Both bacterial STDs affecting same anatomical sites.

Transmitted through sexual contact.

Often asymptomatic, especially in women.

Cause similar symptoms when present.

Lead to similar complications (PID, infertility).

Frequently coinfect (30-40% of gonorrhea cases also have chlamydia).

Differences:

Gonorrhea symptoms typically more severe when present.

Gonorrhea has significant antibiotic resistance; chlamydia remains easily treatable.

Gonorrhea more likely to cause disseminated infection.

Testing uses same methods (NAAT).

Treatment differs: Gonorrhea requires injection; chlamydia treated with oral antibiotics alone.

Why both are tested and treated together:

High coinfection rate means treating only one leaves other untreated.

Symptoms don’t distinguish between them.

Current gonorrhea treatment protocols include coverage for both.

Pharyngeal and Rectal Gonorrhea

Infections at these sites have special characteristics.

Pharyngeal (throat) gonorrhea:

Common in people performing oral sex.

Usually completely asymptomatic (90%+).

May cause mild sore throat.

Harder to treat—more treatment failures.

Important reservoir for transmission and resistance development.

Test of cure recommended after treatment.

Testing requires specific throat swab—urine or genital swabs miss it.

Rectal gonorrhea:

Common in people engaging in receptive anal sex.

Often asymptomatic (60-80%).

Symptoms: Discharge, pain, itching, bleeding, painful bowel movements.

Can cause proctitis (rectal inflammation).

Requires specific rectal swab testing—other samples miss it.

Same treatment as urogenital gonorrhea.

Importance of site-specific testing:

Pharyngeal and rectal infections are missed without appropriate swabs.

People may have infection at these sites with negative urine tests.

Must disclose sexual practices to doctor for comprehensive testing.

Gonorrhea Reinfection

Reinfection is common and doesn’t indicate treatment failure.

Reinfection rates:

20-30% of treated individuals become reinfected within 3-6 months.

Higher rates in adolescents and young adults.

Causes of reinfection:

Sex with untreated partner (most common).

Sex with new infected partner.

Both partners weren’t treated simultaneously.

Partner didn’t complete treatment.

Preventing reinfection:

Ensure all partners from exposure period are treated.

Abstain from sex until both you and partners complete treatment (7 days after single-dose therapy).

Use condoms consistently with new partners.

Get tested again 3 months after treatment to detect reinfection.

If repeatedly reinfected, consider whether partners are truly being treated or if condom use is adequate.

Reinfection vs. treatment failure:

Reinfection: New exposure after successful treatment.

Treatment failure: Persistent infection despite antibiotics due to resistant bacteria.

Timing and partner treatment history help distinguish.

Treatment failure requires culture and sensitivity testing to guide alternative antibiotics.

Confidential Testing and Treatment

We understand STD testing and treatment involves sensitive matters requiring discretion.

Privacy protections:

Private consultation rooms ensuring conversations aren’t overheard.

Anonymous testing available if desired.

Discreet billing without explicit service descriptions.

Medical information never shared without written permission.

Electronic records with strict security protocols.

Judgment-free approach:

No moral judgments about sexual practices or partner numbers.

Honest discussion allows optimal care and comprehensive testing.

Respectful treatment regardless of sexual orientation, gender identity, or relationship structure.

Focus on health outcomes, not behavior evaluation.

Understanding of unique challenges facing travelers and expats.

Partner notification support:

Guidance on how to inform partners.

Anonymous notification resources available.

Partner medication provision eliminating partners’ need to visit clinic.

Support navigating difficult conversations.

Hotel Visit Gonorrhea Services

For maximum privacy and convenience, we provide comprehensive gonorrhea testing and treatment through hotel visit services.

Mobile sexual health advantages:

Complete confidential consultation in absolute privacy of your hotel room.

Sample collection (urine or swabs) for laboratory testing.

Rapid point-of-care testing when available for immediate preliminary results.

Immediate treatment initiation (ceftriaxone injection, oral medications) if rapid test positive.

Partner medication provision for expedited partner therapy.

Clear counseling about transmission prevention and follow-up testing.

Follow-up visit for test of cure or treatment response assessment.

Discreet service without need to visit clinic for sexual health concerns.

Our medical team provides professional, confidential gonorrhea care throughout Bangkok when you need private services.

Gonorrhea Testing and Treatment Costs

Professional gonorrhea care in Bangkok offers exceptional value compared to Western countries.

Typical costs:

Sexual health consultation: 1,500-2,500 THB ($45-75 USD)

Complete gonorrhea testing and treatment: 4,000-7,000 THB ($120-210 USD)

Comprehensive STD panel (gonorrhea, chlamydia, HIV, syphilis, hepatitis): 6,000-10,000 THB ($180-300 USD)

Hotel visit services add 2,000-3,000 THB ($60-90 USD).

These represent 60-80% savings compared to US/UK/Australian costs.

Insurance coverage:

STD testing and treatment typically covered when medically indicated (symptoms or documented exposure).

Routine screening coverage varies by policy.

We provide comprehensive documentation for insurance claims.

Pre-existing condition exclusions don’t apply to new infections.

Contact Us for Confidential Gonorrhea Care

Don’t let embarrassment or privacy concerns prevent you from protecting your sexual health. Gonorrhea is common, treatable, and our medical team provides completely confidential, judgment-free care.

Contact us via WhatsApp at +66950735550 for discreet gonorrhea testing and treatment appointments at our clinic or request private hotel visit services. Our English-speaking doctors provide comprehensive sexual health care with the respect and confidentiality you deserve.

Early treatment prevents serious complications including infertility and protects your partners from infection.

Frequently Asked Questions About Gonorrhea

How soon after exposure should I get tested for gonorrhea?

Gonorrhea NAAT tests can detect infection within 1-2 weeks of exposure with good accuracy. Testing immediately after exposure may produce false negatives if infection hasn’t established yet. If you have symptoms (discharge, burning urination), test immediately regardless of timing since symptoms indicate established infection. If asymptomatic after known exposure, testing at 2 weeks post-exposure provides reliable results. Many doctors recommend testing at both 2 weeks (catches early infections) and 3 months (conclusive) after high-risk exposures.

Can I get gonorrhea from oral sex?

Yes, absolutely. Gonorrhea transmits efficiently through oral-genital contact in both directions—giving or receiving oral sex. Pharyngeal (throat) gonorrhea from receiving oral sex is actually quite common, though usually asymptomatic. You can then transmit throat gonorrhea back to someone’s genitals through oral sex. This is why comprehensive STD testing includes throat swabs for people who engage in oral sex, and why condoms or dental dams are recommended even for oral sex if STD status is unknown.

Why do I need an injection—can’t I just take pills?

Oral-only antibiotic treatment for gonorrhea is no longer recommended due to widespread antibiotic resistance. The ceftriaxone injection is currently the most reliable treatment ensuring adequate antibiotic concentrations to kill resistant gonorrhea strains. While inconvenient, the injection significantly increases cure rates compared to oral antibiotics alone. The doxycycline pills you also receive provide additional gonorrhea coverage plus treat possible chlamydia coinfection. This dual-therapy approach (injection plus pills) is essential to successfully treat gonorrhea given current resistance patterns.

If I test positive for gonorrhea, does that mean my partner cheated?

Not necessarily. Gonorrhea can be asymptomatic for extended periods—someone could have had gonorrhea before your relationship began and never knew. If you’ve been together less than a year, either of you could have brought asymptomatic infection into the relationship from previous partners. However, if you’ve been in a long-term mutually monogamous relationship for over a year and both tested negative before, new gonorrhea typically indicates someone had outside sexual contact. This is a difficult conversation best approached with open communication rather than assumptions.

Do I really need to get retested after treatment—won’t the antibiotics definitely cure it?

For most urogenital gonorrhea, current treatment protocols have high cure rates (95%+). However, retesting (test of cure) is recommended for pharyngeal gonorrhea (throat infections are harder to clear), anyone who received alternative treatment regimens, pregnant women, and anyone with persistent symptoms. Beyond that, rescreening at 3 months is strongly recommended for everyone to detect reinfection, which occurs in 20-30% of people—usually from untreated partners or new exposures. Reinfection rates are high enough that 3-month rescreening catches many new infections preventing complications.